Episode 319 -- Deep Dive into SCG Plastics' $20 Million Settlement with OFAC for Violations of the Iran Sanctions Program
Joint Venture Basics for Large and Small Contractors
Bidding for Major Contracts? Compliance Requirements You Should Prepare for Now
Marriages don't last forever: How to terminate a Joint Venture - and come out of it relatively unscathed. Podcast episode 2
Marriages don't last forever - When Joint Ventures go wrong. Podcast episode 1
Construction Webinar Series: Building Compliance: Construction Industry Concerns Under FCA
Ashley Coselli and Daniel Wendt on Difficult Anti-Corruption Due Diligence Projects
Teeming with Teaming Agreements: Navigating Strategic Alliances in the Federal Marketplace
CIO-SP4 Is Ready To Launch: Is Your Business Equipped to Compete?
Roadmap to Joint Venture Agreements: Legal and Accounting Considerations
M&A Webinar - Trendspotting: The Rise of the Atypical Deal
SBA’s Final Rule on SBA’s MP Program, Joint Ventures, Affiliation and 8(a) Regulations
SBA’s Final Rule on Mentor-Protégé Programs: Key Changes for Government Contractors
Growth Strategies for Small Businesses Moving to Mid-Tier
Litigating During COVID: What You Need to Know
Shoot for the STARS: Q&A with SBA’s John Klein on GSA's 8(a) STARS III RFP
Williams Mullen's COVID-19 Comeback Plan: Selling Products and Services to the Federal Government
Day 18 of One Month to More Effective Compliance for Business Ventures-Financial Review of Your Business Venture Partner
Day 15 of One Month to More Effective Compliance for Business Ventures- Tying It All Together for Joint Ventures
Day 14 of One Month to More Effective Compliance for Business Ventures-Auditing Joint Ventures
In January 2022, Biogen Inc. announced it had reached an agreement to sell its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics. On April 20, 2022, Samsung Biologics and Biogen announced that...more
Last week, Biogen Inc. announced it had reached an agreement to sell its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics for an aggregate consideration of up to $2.3 billion. According to a...more
As we previously reported, Biogen has exercised its option to purchase additional shares of Samsung Bioepis, increasing Biogen’s ownership in the Samsung Bioepis joint venture from approximately 5.4% to approximately...more
As we previously reported, on April 24, 2018, Biogen announced that it had plans to exercise an option to acquire up to a 49.9% equity stake in Samsung Bioepis, its joint venture with Samsung BioLogics. Yesterday, Biogen...more
Samsung Bioepis – the joint venture between Samsung and Biogen Idec – has started a phase III clinical trial for a biosimilar version of Roche’s cancer drug Avastin (bevacizumab). Bevacizumab slows the growth of new blood...more